Drospirenone And Ethinyl Estradiol
Product Images NDC 75834-116

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 75834-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (Image 01)

A forest plot chart depicting the risk of venous thromboembolism (VTE) associated with Drospirenone and ethinyl estradiol tablets (3mg/0.03mg) compared to LNG-containing combination oral contraceptives. The chart lists multiple studies grouped as prospective cohort studies, retrospective cohort studies, case-control studies, and studies of non-fatal idiopathic cases, showing hazard ratios, rate ratios, or odds ratios with confidence intervals on a logarithmic scale from 0.1 to 10.*

FDA Label Image

Image-02 (Image 02)

A horizontal bar chart titled 'Likelihood of Developing a VTE' compares the number of women with a blood clot out of 10,000 women years across four groups: Non-Pregnant Non-COC users, COC users, Pregnant women, and Postpartum women (12 weeks only). The chart shows ranges for each group, highlighting increasing risk from Non-COC users to Postpartum women.*

FDA Label Image

Image-03 (Image 03)

Chemical structures of Drospirenone and Ethinyl Estradiol. The image shows detailed molecular diagrams for each active ingredient labeled clearly below each structure.*

FDA Label Image

Image-04 (Image 04)

An illustration showing a vertical scale of pregnancy rates per 100 women in one year ranging from fewer than 1 to 85 or more. It categorizes birth control methods according to effectiveness, with implants, injections, intrauterine devices, sterilization, birth control pills, skin patches, and vaginal rings at the lower pregnancy end; condoms and diaphragms in the middle; and no sex during fertile days, spermicide, and withdrawal higher up; no birth control at the highest pregnancy rate end.*

FDA Label Image

Image-05 (Image 05)

The image shows a tablet calendar blister card for Drospirenone and ethinyl estradiol, 3 mg/0.02 mg, by Nivagen Pharmaceuticals, Inc. It includes 28 circular tablet sites arranged in rows labeled Sunday through Saturday for four weeks. Pink circles indicate active tablets, and white circles indicate inactive tablets, with instructions for use printed beside them.*

FDA Label Image

Image-06 (Image 06)

A bar chart comparing the number of women with a blood clot out of 10,000 women years (WY) in four groups: non-pregnant non-COC users (range 1 to 5), COC users (range 3 to 9), pregnant women (range 5 to 20), and postpartum women within 12 weeks (range 40 to 65). The chart illustrates relative blood clot risks in these groups.*

FDA Label Image

Image-07 (Image 07)

FDA Label Image

Image-08 (Image 08)

Carton label for Drospirenone and Ethinyl Estradiol Tablets, 3 mg/0.02 mg, by Nivagen Pharmaceuticals, Inc. The label states the content of three blister cards with 28 tablets each. It includes dosage strengths, drug name, NDC 75834-116, storage instructions, and distribution information. The design features a pink and white color scheme with the Nivagen Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.